Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230126 · ClinicalTrials.gov registry record · Phase 2
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00230126 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 57 participants.
The verdict
NCT00230126, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
Interventions
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230126
The ClinicalTrials.gov registry entry for NCT00230126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erlotinib is the first listed.
NCT00230126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230126 about?
NCT00230126 is a clinical study titled "OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer". This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
What is the current status of trial NCT00230126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2005-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00230126?
The interventions under investigation include: erlotinib (DRUG).
Who is sponsoring clinical trial NCT00230126?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.